Long-Term Persistence of HCV NS5A Resistance-Associated Substitutions after Treatment with the HCV NS5A Inhibitor, Ledipasvir, without Sofosbuvir. Issue 3 (April 2018)

• Record Type: Journal Article
• Authors: Wyles, David; Mangia, Alessandra; Cheng, Wendy; Shafran, Stephen; Schwabe, Christian; Ouyang, Wen; Hedskog, Charlotte; McNally, John; Brainard, Diana M; Doehle, Brian P; Svarovskaia, Evguenia; Miller, Michael D; Mo, Hongmei; Dvory-Sobol, Hadas
• Is Part Of: Antiviral therapy. Volume 23:Issue 3(2018)
• Page Start: 229
• Page End: 238
• Publication Date: 2018-04
• Subjects: Antiviral agents -- Periodicals; Antiviral Agents -- therapeutic use; Virus Diseases -- therapy; Viruses -- drug effects; Antiviral agents; Periodical; Electronic journals; Periodicals; 616.9106
• DOI: 10.3851/IMP3181
• Languages: English
• ISSNs: 1359-6535

Abstract

Background: Data on persistence of NS5A resistance-associated substitutions (RASs) may have implications for resistance testing approaches and selection of initial and retreatment strategies. Methods: Long-term persistence of NS5A RASs in HCV genotype (GT) 1 infected subjects ( n =76) who did not achieve sustained virological response after receiving ledipasvir (LDV) without sofosbuvir (SOF) and were subsequently enrolled in an ongoing 3-year follow-up registry study was investigated by population or deep sequencing. Results: Of the 76 subjects enrolled, 67 and 9 subjects had GT1a and GT1b infection, respectively. At pretreatment, NS5A RASs were detected in 14% of subjects (11/76) by population sequencing, with three subjects having >1 RAS. All RASs that were detected at pretreatment persisted and were observed at the 96 week visit in the follow-up study (FU96). For the remaining subjects with no detectable RASs at pretreatment, RASs were detected in 98% (63/64) of subjects at virological failure in the parent study and persisted at detectable levels through FU96 in 86% of subjects by deep sequencing (1% cutoff). However, a decline in the quasispecies frequency of most RASs and the number of RASs per subject was observed over time. Phenotypic analysis demonstrated that the majority of NS5A RASs confer similar levels of resistance to LDV and daclatasvir. Conclusions: The majority of NS5A RASs can persist at detectable levels for >96 weeks post-treatment in subjects who failed treatment with regimens containing an NS5A inhibitor without SOF, suggesting relatively high fitness of NS5A RASs even in the absence of drug pressure.